Adagrasib
Krazati · KRAS G12C inhibitor
Creatinine rise; emerging data.
PREGLOMATN
MildOpen →
The Drug Explorer
Search the nephrotoxic landscape
A live index of 240+ anti-cancer agents, cross-filterable by injury signature, drug class, nephron segment, severity, and era. Profiled agents open to a full citation-grounded page; the rest are catalog entries with their signature kidney signal.
33 agents · filtered from 240
Profile
Atezolizumab
Tecentriq · Anti-PD-L1 antibody
Interstitial nephritis; rare glomerular disease.
AINGLOM
ModerateOpen →
Avelumab
Bavencio · Anti-PD-L1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Belantamab mafodotin
Blenrep · Antibody-drug conjugate (BCMA/MMAF)
Myeloma ADC; renal data emerging.
PREGLOM
MildOpen →
Bevacizumab
Avastin · Anti-VEGF antibody
Proteinuria, hypertension, glomerular TMA.
GLOMHTNTMA
ModerateOpen →
Bortezomib
Velcade · Proteasome inhibitor
Rare TMA; reverses myeloma cast nephropathy.
TMAGLOM
ModerateOpen →
Cabozantinib
Cabometyx · VEGFR/MET TKI
Hypertension and proteinuria; nephrotic case reports.
HTNGLOM
ModerateOpen →
Cemiplimab
Libtayo · Anti-PD-1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Clofarabine
Clolar · Purine analog
Capillary-leak / SIRS-like AKI and tumor lysis.
PREATNGLOM
ModerateOpen →
Dasatinib
Sprycel · BCR-ABL TKI
Nephrotic-range proteinuria — a notable signal.
GLOM
ModerateOpen →
Datopotamab deruxtecan (Dato-DXd)
Datroway · Antibody-drug conjugate (TROP2/DXd)
2025 TROP2 ADC; renal signal theoretical, extrapolated from the ADC class.
ATNGLOM
ModerateOpen →
Dostarlimab
Jemperli · Anti-PD-1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Doxorubicin
Adriamycin · Anthracycline
Experimental podocyte model; clinical proteinuria rare.
GLOM
MildOpen →
Durvalumab
Imfinzi · Anti-PD-L1 antibody
ICI-associated AIN.
AINGLOM
ModerateOpen →
Erlotinib
Tarceva · EGFR TKI
Rare minimal-change disease and AKI.
GLOMATN
MildOpen →
Fruquintinib
Fruzaqla · VEGFR TKI
2023 colorectal VEGFR-TKI; hypertension and proteinuria, class effect.
HTNGLOM
ModerateOpen →
Gefitinib
Iressa · EGFR TKI
Rare nephrotic syndrome.
GLOM
MildOpen →
Gemcitabine
Gemzar · Nucleoside analog
Dose-cumulative thrombotic microangiopathy.
TMAHTNGLOM
SevereOpen →
Ibrutinib
Imbruvica · BTK inhibitor
Tumor lysis, hypertension and AKI.
HTNPREGLOM
ModerateOpen →
Interferon-α
Intron A · Cytokine
Collapsing FSGS in APOL1 carriers.
GLOM
SevereOpen →
Lenvatinib
Lenvima · VEGFR TKI
Highest-ranked TKI for hypertension; proteinuria.
HTNGLOM
ModerateOpen →
Mitomycin C
Mutamycin · Antitumor antibiotic
Prototype dose-dependent TMA.
TMAGLOM
SevereOpen →
mTOR inhibitors (everolimus · temsirolimus)
mTOR inhibitor
Podocyte injury → proteinuria and FSGS.
GLOMATN
MildOpen →
Nintedanib
Ofev · VEGFR/FGFR/PDGFR TKI
Proteinuria and rare TMA.
HTNTMAGLOM
MildOpen →
Pamidronate
Aredia · Bisphosphonate
Collapsing FSGS — first drug ever linked.
GLOM
SevereOpen →
Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
Regorafenib
Stivarga · VEGFR TKI
Hypertension and proteinuria.
HTNGLOM
ModerateOpen →
Sirolimus
Rapamune · mTOR inhibitor
Proteinuria, cast nephropathy, delayed graft recovery.
GLOMATN
ModerateOpen →
Tivozanib
Fotivda · VEGFR TKI
Hypertension and proteinuria in RCC.
HTNGLOM
ModerateOpen →
Trastuzumab emtansine (T-DM1)
Kadcyla · Antibody-drug conjugate (HER2/DM1)
Rare nodular regenerative TMA-like signals.
TMAGLOM
ModerateOpen →
Vandetanib
Caprelsa · VEGFR/EGFR/RET TKI
Hypertension; QT prolongation.
HTNGLOM
ModerateOpen →
VEGFR TKIs (sunitinib · sorafenib · pazopanib · axitinib)
VEGFR TKI
Hypertension as an on-target marker; proteinuria.
HTNGLOMTMA
ModerateOpen →
Ziv-aflibercept
Zaltrap · VEGF trap
Hypertension and proteinuria like bevacizumab.
HTNGLOMTMA
ModerateOpen →